Both APC and KRAS mutations synergistically promote cellular transformation and tumor growth3–5, which is attributed to the activation of the RAS-ERK pathway via the aberrant activation of the Wnt/β-catenin signaling caused the loss of APC6–8. The gene discussed is APC; the disease is neoplasm.